[The role of the NMDA-receptor blocker and stimulator ketamine and glycine in the development of a neuropathic pain syndrome]
- PMID: 9376747
[The role of the NMDA-receptor blocker and stimulator ketamine and glycine in the development of a neuropathic pain syndrome]
Abstract
The effect of glycine, ketamine, and their combination in chronic oral administration was studied on a model of the neuropathic pain syndrome. Glycine failed to prevent the pain syndrome but had a therapeutic effect. Ketamine possessed a marked preventive and therapeutic effect. In combined administration the drugs mutually potentiated their action. The effect of glycine and ketamine is based on intensification of spinal glycinergic inhibition, differently directed effect on the NMDA receptors, and intensification of monoaminergic inhibition.
Similar articles
-
The antiallodynic effect of NMDA antagonists in neuropathic pain outlasts the duration of the in vivo NMDA antagonism.Neuropharmacology. 2006 Jul;51(1):12-7. doi: 10.1016/j.neuropharm.2006.02.007. Epub 2006 Apr 17. Neuropharmacology. 2006. PMID: 16616769
-
Prolonged analgesic effect of ketamine, an N-methyl-D-aspartate receptor inhibitor, in patients with chronic pain.J Pharmacol Exp Ther. 1999 May;289(2):1060-6. J Pharmacol Exp Ther. 1999. PMID: 10215688 Clinical Trial.
-
Low dose ketamine: a therapeutic and research tool to explore N-methyl-D-aspartate (NMDA) receptor-mediated plasticity in pain pathways.J Psychopharmacol. 2007 May;21(3):259-71. doi: 10.1177/0269881105062484. J Psychopharmacol. 2007. PMID: 17591654 Review.
-
The NMDA receptor complex: a long and winding road to therapeutics.IDrugs. 2005 Mar;8(3):229-35. IDrugs. 2005. PMID: 15772895 Review.
-
NMDA receptor antagonists and pain: ketamine.Vet Clin North Am Equine Pract. 2010 Dec;26(3):565-78. doi: 10.1016/j.cveq.2010.07.009. Vet Clin North Am Equine Pract. 2010. PMID: 21056300 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical